Tumor necrosis factor-α -G308A polymorphism is associated with liver pathological changes in hepatitis C virus patients

Table 2 Distribution of tumor necrosis factor α -G308A polymorphism in controls and hepatitis C virus infected patients with different fibrosis grades (F0-F4) n (%)

Polymorphism of TNFα -308	Controls (n = 60)	HCV Patients (n = 120)	F0 patients (n = 30)	F1 patients (n = 30)	F2-3 patients (n = 30)	F4 patients (n = 30)
GG genotype	40 (66.6)	48 (40.0)	18 (60.0)	13 (43.3)	10 (33.3)	7 (23.3)
GA genotype	18 (30.0)	57 (47.5)	10 (33.3)	15 (50.0)	16 (53.4)	16 (53.4)
AA genotype	2 (3.3)	15 (12.5)	2 (6.7)	2 (6.7)	4 (13.3)	7 (23.3)
GA + AA	20 (33.3)	72 (60.0)	12 (40.0)	17 (56.7)	20 (66.6)	23 (76.6)
G allele	98 (81.7)	153 (63.8)	46 (76.7)	41 (68.3)	36 (60.0)	30 (50.0)
A allele	22 (18.3)	87 (36.3)	23 (23.3)	19 (31.7)	24 (40.0)	30 (50.0)

Genotyping of TNFα -G308A was conducted and distribution of different genotypes and alleles was calculated as percentage and compared in 60 controls and 120 chronic HCV patients with different fibrosis grades: F0 (n = 30), F1 (n = 30), F2-F3 (n = 30), F4 (n = 30). TNFα: Tumor necrosis factor alpha; HCV: Hepatitis C virus.